60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
28 août 2024 14h48 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
06 août 2024 09h26 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
24 mai 2024 16h30 HE
|
BIO-key International, Inc.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq regarding untimely filing of its form 10-Q.
Evaxion Receives Nasdaq Notification
10 mai 2024 17h00 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Auddia Announces Closing of $2.3M PIPE to Eliminate Debt and Regain Nasdaq Compliance
29 avr. 2024 08h00 HE
|
Auddia Inc.
BOULDER, CO, April 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), a developer of a proprietary AI platform for audio and...
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
22 avr. 2024 16h30 HE
|
BIO-key International, Inc.
BIO-key International, Inc. Received Notice of Non-Compliance from Nasdaq regarding filing all required periodic financial reports with the SEC.
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 févr. 2024 08h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
08 janv. 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
03 nov. 2023 16h30 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
BIO-key International Announces Pricing of $3.75 Million Public Offering
30 oct. 2023 14h21 HE
|
BIO-key International, Inc.
BIO-key International Announces Pricing of $3.75 Million Public Offering.